New cocktail aims to snuff out residual AML before it returns

NCT ID NCT07148180

Recruiting now Disease control Sponsor: Jacqueline Garcia, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three drugs—tagraxofusp, azacitidine, and venetoclax—in adults with acute myeloid leukemia (AML) who are in remission but still have tiny amounts of cancer cells that standard tests miss. The goal is to see if the combo can safely clear these hidden cells and prevent relapse. The trial enrolls 31 participants across multiple sites.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tagraxofusp, azacitidine, and venetoclax
What this could lead to: If successful, this combination could help eliminate hidden leukemia cells and reduce the chance of the cancer coming back.
What could go wrong: This is an early-phase trial with only 31 participants, so safety and effectiveness are not yet proven. Side effects from the drug combination may occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloblastic leukemia with maturation acute myeloid leukemia hematopoietic and lymphoid system neoplasm leukemia Neoplasm, Residual

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKAEMIA (AML) BLOOD CANCER BLOOD CANCERS LEUKEMIA

Contacts and locations

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.